Kick Pharmaceuticals Inc. entered into an agreement to acquire Glenbriar Technologies Inc. (CNSX:GTI.X) for CAD 8.5 million in a reverse merger transaction on October 30, 2020. The agreement contemplates that Glenbriar will issue up to 348 million common shares of Glenbriar to the shareholders of Kick. That amount of shares assumes a concurrent private placement by Kick of CAD 1.63 million. In a related transaction, Glenbriar entered in to a non-brokered private placement of up to CAD 1.5 million. The transaction is subject to exchange approval, further due diligence, receipt of all regulatory approvals, third party approval, the board of directors of combined company shall be consist of three (3) directors, the senior management team of combined company shall consist of those officers appointed by the new board of directors of the combined company, the auditors of the combined company being Baker Tilley WM LLP, Dissent Rights, the shareholders of Kick shall have approved the amalgamation, the directors of GTI shall have approved and GTI shall have completed the consolidation and approval for listing on the CSE. The transaction will be considered a fundamental change pursuant to the policies of the Canadian Securities Exchange, subject to shareholder and CSE review. Odyssey Trust Company acted as transfer agent and Rick Skeith of Dentons Canada LLP acted as legal advisor to Glenbriar Technologies.

Kick Pharmaceuticals Inc. completed the acquisition of Glenbriar Technologies Inc. (CNSX:GTI.X) in a reverse merger transaction on September 20, 2021. The acquisition was made in exchange of 183,067,857 of Glenbriar common shares. Glenbriar Technologies is advised that its shares will commence trading under the symbol LUV on the CSE on Thursday, September 30, 2021. As part of the transaction, Zach Stadnyk of Vancouver, BC, has joined the board and has assumed the role of president and CEO, with Doug Taylor remaining on the board.